Buprenorphine Maintenance Use

Continue it through surgery - Current guidelines recommend continuing buprenorphine throughout the intraoperative period. Abrupt discontinuation precipitates withdrawal and complicates pain control, and stopping maintenance therapy carries a high rate of return to harmful opioid use — in one multicenter trial, 82% of 516 participants had recurrence of harmful use within a month of perioperative buprenorphine cessation. Continuing it has not been associated with worse outcomes, and one series reported lower postoperative opioid requirements and better early recovery pain scores when it was continued rather than held.

⚠ The 48-72 hour hold is contested, not settled - Many institutions still stop maintenance buprenorphine 48 to 72 hours before surgery. That practice rests on scant data and on three inferences that have not held up: that a partial agonist cannot be a potent analgesic, that a respiratory-depression ceiling implies an analgesic ceiling, and that buprenorphine fully blockades co-administered opioids. The evidence on either side is weak — Goel et al graded the recommendation to continue as GRADE Level 5. Follow your institution's protocol and coordinate with the patient's prescriber rather than treating either approach as proven.

Full agonists still work, at higher doses - Because ordinary maintenance dosing leaves receptors unoccupied, fentanyl, hydromorphone, or sufentanil can be given on top of buprenorphine. Usual doses typically don't work; roughly 1.5 to 2 times the usual dose may be needed. Start at the usual dose and titrate up to effect rather than opening with a large dose.

High daily doses are the exception - At 24 mg/day or more sublingually, mu receptor availability is minimal and common full agonists may be ineffective. For elective painful surgery in that group, consider a careful taper to a lower daily dose arranged in advance with the prescriber. The receptor effects are reversible — within 24 hours of reducing a high dose, about 40% of receptors become unoccupied again. Standard maintenance dosing is 8 mg twice daily or less.

Redistribute the daily dose - One published strategy keeps the same total daily dose but splits it to open receptors on the day of surgery: 8/2 mg twice daily becomes 4/1 mg four times daily. A related protocol gives 8 mg buprenorphine/naloxone twice daily the day before surgery to prevent cravings, then 4 mg twice daily on the day of surgery and afterward.

Multimodal is the plan, not an add-on - Published perioperative protocols give acetaminophen 1,000 mg PO, gabapentin 300 mg PO or pregabalin 75 mg PO, and celecoxib 200 mg PO 60 minutes before the procedure. Intraoperatively: dexamethasone 0.1 mg/kg IV (max 10 mg), magnesium sulfate 2 g over 15 minutes before incision, ketamine 0.25-0.5 mg/kg IV then a subanesthetic infusion at 0.1-0.5 mg/kg/hr, dexmedetomidine 0.2-1 mcg/kg/hr, lidocaine 1.5 mg/kg/hr where regional isn't being used, and esmolol 0.5 mg/kg on induction then 10-50 mcg/kg/min. Ketorolac 15 mg IV only if celecoxib wasn't given, or 12 hours after it.

Regional is the highest-yield move - Use continuous techniques where the surgery allows — epidural or peripheral nerve catheters — and keep them running postoperatively. For emergent cases with no time to plan, regional and non-opioid modalities carry most of the load.

Naloxone is a poor rescue - Reversing buprenorphine is difficult; doses up to 10 mg of naloxone may be needed, and because buprenorphine substantially outlasts naloxone an infusion would be required to hold the reversal. Don't build a plan that depends on being able to reverse it.

Minimally invasive cases are different - For procedures with little or no expected postoperative opioid requirement — cardioversion, endoscopy, cataracts, EP procedures — continue the home dose; the multimodal regimen can be modified or skipped.

Discharge on the maintenance dose - Continue the scheduled multimodal medications and the buprenorphine. Subanesthetic ketamine below 0.3 mg/kg/hr needs a unit that permits infusions. Discharge on the preoperative maintenance dose, involve the acute pain service, and communicate with the outpatient buprenorphine prescriber.

Watch the CYP3A4 interactions - Buprenorphine is metabolized by hepatic CYP3A4 and intestinal mucosa to the active metabolite norbuprenorphine. Patients on erythromycin, diltiazem, ketoconazole, ritonavir, verapamil, or ciprofloxacin have reduced clearance and a higher overdose risk.

Cross-reference - For the alcohol side of substance use, see Substance Abuse - Alcohol and the Alcohol Withdrawal Syndrome entry.

Buprenorphine is a semisynthetic opioid used as medication-assisted treatment for opioid use disorder: a partial agonist at the mu receptor and an antagonist at kappa. Its high mu affinity — roughly 1,000 times that of morphine and 10 times that of naloxone — combined with a long and highly variable sublingual half-life is what creates the perioperative problem, because full agonists compete poorly for whatever receptor is left.

Occupancy is dose-dependent and incomplete. At therapeutic maintenance doses buprenorphine occupies about 80% to 95% of mu receptors; at 8 to 12 mg daily up to 20% remain available, while at 24 to 32 mg daily availability is minimal. A ceiling effect exists for respiratory depression and for euphoria, but a ceiling for analgesia has never been demonstrated — trial data show a dose-response effect for analgesia.